Peptides Gain Traction In Drug Development

Van Arnum, Patricia
June 2012
Pharmaceutical Technology;Jun2012, Vol. 36 Issue 6, p42
Trade Publication
The article reports that peptide drug development is gaining traction. According to the Peptide Therapeutics Foundation analysis, the average number of peptide candidates entering clinical development rose to 16.8 per year through 2000-2008. It cites partnerships among pharmaceutical companies to resolve problems in peptide drug development such as one between Aileron Therapeutics and Roche for stapled-peptide drug development.


Related Articles

  • Roche and Aileron Therapeutics Expand Collaboration for Stapled Peptide Drugs.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p602 

    The article reports on initiation of a program by Roche to expand its collaboration with Aileron Therapeutics Inc. It notes that the program aims to collaborate on the discovery, development and commercialization of Stapled Peptide drugs. It adds that the 1.1-billion-dollar drug development...

  • Aileron, Roche Enter Peptides Deal Worth up to $1.26B. Hollingsworth, Catherine // BioWorld Today;8/25/2010, Vol. 21 Issue 164, p1 

    The article reports that Roche AG will pay Aileron Therapeutics Inc. to develop therapeutics based on the company's peptides platform aimed at previously considered undruggable targets. The deal included up front payments of at least 25 million U.S. dollars and 1.1 billion U.S. dollars in...

  • A Marriage of Small Molecules and Biologics. Van Arnum, Patricia // Pharmaceutical Technology;May2011, Vol. 35 Issue 5, p56 

    The article discusses the integration between the modalities of small molecules and peptide synthesis which are essential for drug development in the U.S. It highlights the utilization of stapled peptides which gained prominence when F. Hoffmann-La Roche Ltd. signed a contract with...

  • News in brief.  // Nature Reviews Drug Discovery;Jan2010, Vol. 9 Issue 1, p9 

    The article offers news briefs related to drug discovery. It announces the cancer uncertainties database launched by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. It notes that director John Jenkins withdrew permission for reviewers to extend the Prescription...

  • Roche preoperative treatment found effective against breast cancer.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p9 

    The article reports on results of a clinical trial initiated by Roche, which suggest that the combination of oral Xeloda and Taxotere may be an active and well-tolerated neoadjuvant treatment option for women with invasive breast cancer. In the multi-center, open-label trial, a majority of the...

  • ROCHE HOLDING AG.  // MondayMorning;3/11/2013, Vol. 21 Issue 9, p1 

    The article offers information on Roche Holding AG. that has developed a drug Rituxan to cure deadly skin diseases such as pemphigus. It informs that the drug may help to replace the use of steroids as the standard treatment drug for the disease. It includes information on the drug trial on...

  • Roche Licenses Chiasma's Late-Stage Oral Acromegaly Therapy. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 2, p22 

    The article reports on the collaboration of Chiasma, an Israeli biotech, with Roche for the development and commercialization of its drug Octreolin® to treat acromegaly. It mentions that the drug has completed 4 clinical trials and heads to its Phase III acromegaly trial. It states that the...

  • Other News To Note.  // BioWorld Today;11/17/2011, Vol. 22 Issue 224, p7 

    This section offers news briefs on the biotechnology industry as of November 2011. Aileron Therapeutics and Roche Holdings AG expanded their partnership to develop and commercialize stapled peptide drugs. Aldagen Inc. published a paper about the mechanisms by which its cell therapy products...

  • Aileron's $30M Series E to 'Activate' Clinical Development. Shaffer, Catherine // BioWorld Today;11/19/2013, Vol. 24 Issue 223, p1 

    The article reports that American pharmaceutical company Aileron Therapeutics Inc. got a 30 million dollars financing from investors to pursue the clinical development of ALRN-6924, the company's lead hope for a tumors treatment and continue the development of other pipeline products . The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics